Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets (Details)

v3.25.0.1
Intangible Assets (Details) - USD ($)
3 Months Ended 6 Months Ended
Feb. 25, 2024
Sep. 19, 2022
Aug. 23, 2021
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]              
Amortization of Intangible Assets       $ 5,000 $ 5,000 $ 10,000 $ 10,000
Stock Purchase Agreement | RubrYc Therapeutics              
Finite-Lived Intangible Assets [Line Items]              
Investment in RubrYc     $ 7,500,000        
Asset Purchase Agreement | RubrYc Therapeutics              
Finite-Lived Intangible Assets [Line Items]              
Investment in RubrYc   $ 1,342,000          
PD-1 Asset Purchase Agreement | Otsuka Pharmaceutical | Intellectual Property              
Finite-Lived Intangible Assets [Line Items]              
Proceeds from sale of intellectual property $ 1,000,000            
Potential contingent payments related to sale of intellectual property $ 52,500,000